65,437 trials
Thrombosis, Venous
Primary: Number of Participants With at Least on Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 47 — 13; 88 participants — p=<0.001
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Guanfacine — 2.55; 2.97 ng/ml
Infections, Papillomavirus
Primary: Number of Cytokine-positive CD4/CD8 Cells Per Million in Tests Producing at Least 2 Different Cytokines — 877.4; 19.5; 738.5; 22.3 cells per million CD4/CD8 T-cells
Diabetes Mellitus, Type 1
Primary: Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion — 68.4; 62.1; 61.3 percentage of patients — p=0.039
Cataracts
Primary: Percent Loss of Endothelial Cells — 9.48; 15.66; 23.69; 25.70 Percent Loss
Hypercholesterolemia
Primary: Percent Change in Pre- and Post-treatment Reductions of Low-density Lipoprotein Cholesterol (LDL-C) Levels Between the Approved H.E.L.P. System and the Modified H.E.L.P…
Infections, Rotavirus
Primary: Number of Subjects With at Least One >= Grade "2" Fever, Vomiting or Diarrhoea — 78 subjects
Allergies
Primary: Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet. — 149; 33; 38 participants — p=<0.0001
Cataracts
Primary: Uncorrected and Best Corrected Visual Acuities (Near and Distance) — 0.02; 0.01; 0.00; -0.03 logMAR
Postmenopause
Primary: Change From Baseline in Estrogen Receptor Beta (ERbeta) -Specific Gene Signature After Treatment With 2 mg, 0.5 mg, or no Estradiol (Placebo) at Day 7 — 0.028; -0.011…
Rhinitis, Allergic, Seasonal
Primary: The Average Change From Baseline to Endpoint (6 Hours Post-dosing) in Nasal Congestion for Phenylephrine Compared With Placebo — 2.20; 2.20; -0.12; -0.18 Units on a…
Schizophrenia
Primary: Change From Baseline to End Point in the Triglycerides (TG) to High Density Lipoprotein (HDL) Ratio (TG:HDL Ratio) — -0.08; 0.42 Ratio — p=< 0.0001
Obstructive Sleep Apnea · Hypopnea
Primary: Maintenance of Wakefulness Test (MWT) — 2.2; 1.7; -1.7 Minutes — p=0.0001
Osteoporosis
Primary: Change in Marker of Bone Metabolism, PINP — -13.1; 20.0; 90.8; 97.2 Percent change from baseline — p=<0.001
Non-Hodgkin Lymphoma · Hodgkin Disease
Primary: Summary of Adverse Events (AEs) — 9; 13; 7; 12 participants